Egetis Therapeutics Ab
About
Egetis Therapeutics Ab — investor relations, events, news, and company updates on 6ix.
Latest News
Mar 27 2026
Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate(R) (tiratricol) for MCT8 Deficiency
Mar 9 2026
Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S.
Mar 2 2026
Egetis Therapeutics Launches Educational Websites on MCT8 Deficiency for Physicians and Caregivers